tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jan 17;10(1):128.
doi: 10.3390/vaccines10010128.
Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2-A Candidate for Passive Immunization against COVID-19
Hendris Wongso[SUP] 1 [/SUP], Isa Mahendra[SUP] 1 [/SUP], Wyanda Arnafia[SUP] 2 [/SUP], Idar Idar[SUP] 3 [/SUP], Muhammad Yusuf[SUP] 4 5 [/SUP], Arifudin Achmad[SUP] 6 [/SUP], Holis A Holik[SUP] 7 [/SUP], Ahmad Kurniawan[SUP] 1 [/SUP], Iim Halimah[SUP] 1 [/SUP], Maula E Sriyani[SUP] 1 [/SUP], Teguh H A Wibawa[SUP] 1 [/SUP], Muhamad B Febrian[SUP] 1 [/SUP], Yanuar Setiadi[SUP] 1 [/SUP], Eva M Widyasari[SUP] 1 [/SUP], Isti Daruwati[SUP] 1 [/SUP], Crhisterra E Kusumaningrum[SUP] 1 [/SUP], Toto Subroto[SUP] 4 5 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19.
Keywords: COVID-19; IgY anti-RBD spike SARS-CoV-2; passive immunization; preclinical evaluation; radiolabeled IgY.
. 2022 Jan 17;10(1):128.
doi: 10.3390/vaccines10010128.
Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2-A Candidate for Passive Immunization against COVID-19
Hendris Wongso[SUP] 1 [/SUP], Isa Mahendra[SUP] 1 [/SUP], Wyanda Arnafia[SUP] 2 [/SUP], Idar Idar[SUP] 3 [/SUP], Muhammad Yusuf[SUP] 4 5 [/SUP], Arifudin Achmad[SUP] 6 [/SUP], Holis A Holik[SUP] 7 [/SUP], Ahmad Kurniawan[SUP] 1 [/SUP], Iim Halimah[SUP] 1 [/SUP], Maula E Sriyani[SUP] 1 [/SUP], Teguh H A Wibawa[SUP] 1 [/SUP], Muhamad B Febrian[SUP] 1 [/SUP], Yanuar Setiadi[SUP] 1 [/SUP], Eva M Widyasari[SUP] 1 [/SUP], Isti Daruwati[SUP] 1 [/SUP], Crhisterra E Kusumaningrum[SUP] 1 [/SUP], Toto Subroto[SUP] 4 5 [/SUP]
Affiliations
- PMID: 35062789
- DOI: 10.3390/vaccines10010128
Abstract
The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19.
Keywords: COVID-19; IgY anti-RBD spike SARS-CoV-2; passive immunization; preclinical evaluation; radiolabeled IgY.